Quris, an artificial intelligence (AI) innovator in the pharmaceutical arena, has signed an agreement with Merck KGaA allowing Merck KGaA to assess Quris’s BioAI safety prediction platform, comparing it to traditional in vitro and in vivo approaches.    Quris’s BioAI safety prediction platform introduces a unique concept (18 granted and pending patents), which integrates miniaturized human tissues on a chip, nano-sensing, and machine learning, to predict which drug candidates will work safely ...